Compare AKBA & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | IIIV |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 642.1M |
| IPO Year | 2014 | 2018 |
| Metric | AKBA | IIIV |
|---|---|---|
| Price | $1.42 | $21.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $5.92 | ★ $33.33 |
| AVG Volume (30 Days) | ★ 3.1M | 422.3K |
| Earning Date | 03-12-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.51 |
| Revenue | ★ $225,071,000.00 | $213,608,000.00 |
| Revenue This Year | $52.41 | $8.32 |
| Revenue Next Year | $21.57 | $7.26 |
| P/E Ratio | ★ N/A | $41.29 |
| Revenue Growth | ★ 32.49 | 13.38 |
| 52 Week Low | $1.30 | $19.89 |
| 52 Week High | $4.08 | $33.97 |
| Indicator | AKBA | IIIV |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 37.33 |
| Support Level | $1.35 | $21.52 |
| Resistance Level | $1.44 | $23.00 |
| Average True Range (ATR) | 0.08 | 1.29 |
| MACD | 0.01 | -0.23 |
| Stochastic Oscillator | 42.50 | 31.45 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.